Table 3.
Preferred Term — no. of participants (%) | Placebo (N=1306) | REGEN-COV 1200 mg SC (N=1311) | |
---|---|---|---|
| |||
Covid-19 | 112 (8.6) | 15 (1.1) | |
Asymptomatic Covid-19 | 108 (8.3) | 54 (4.1) | |
Headache | 46 (3.5) | 24 (1.8) | |
Injection site reaction | 19 (1.5) | 55 (4.2) |
Regardless of the SARS-CoV-2 serology status at baseline. SC denotes subcutaneous.